Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Phase 2 N=50 SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients
Phase 2 N=24 Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
Hepatocellular Carcinoma
Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Phase 2 N=60 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Hepatocellular Carcinoma
Primary: Overall Response Rate — 6; 30; 17; 0 Participants
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=30 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Phase 2 N=78 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536
N/A N=76 Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Phase 2 N=117 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 3 N=400 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Carcinoma, Hepatocellular
Primary: Overall Survival — 8.7; 6.8 months
Phase 3 N=565 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391
Phase 1 N=10 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Hepatocellular Carcinoma
Primary: Number of Adverse Events — 12; 2; 8; 4 events
Phase 2 N=224 Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Overall Survival (OS) - Stratified Analysis, Randomized Portion — 12.7; 9.7 months — p=0.2872
Phase 2 N=54 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Phase 2 N=67 Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular
Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients
Phase 3 N=546 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Carcinoma
Primary: Overall Survival (OS) — 7.56; 7.33 Months
Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=24 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Time to Progression (TTP) — 3.5 months
Phase 3 N=707 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049
Phase 3 N=602 A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 324; 241 days — p=0.00583
Phase 2 N=29 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
Phase 2 N=66 c-Met Second-Line Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…
N/A N=131 Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 2 N=97 A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities